Sai Parenterals Subsidiary Signs ₹1,300 Crore Australia Supply Deal; Shares Surge

Mumbai, July 2: Shares of Sai Parenterals Ltd. climbed in early trade after the company announced that its wholly owned subsidiary, Noumed Pharmaceuticals Pty Ltd, has entered into an exclusive over-the-counter (OTC) medicines supply agreement with one of Australia’s leading pharmacy networks.

According to the exchange filing, the agreement carries a contract value of AUD 202 million, equivalent to roughly ₹1,300 crore, making it one of the largest international commercial wins disclosed by the company.

The agreement takes effect from July 1, 2026, and has an initial tenure of 7.5 years. It also includes an option to extend the arrangement by another three years, subject to mutual agreement between the parties.

The name of the customer has not been disclosed. The company described it only as Australia’s leading pharmacy network, citing the commercial nature of the agreement.

Sai Parenterals also clarified that the contract has been awarded by an international customer, is not a related-party transaction, and that neither its promoters nor promoter group entities have any interest in the awarding organisation.

Stock Market Snapshot

The announcement triggered strong buying interest in the stock during Thursday’s session.

As of 9:19 AM IST on July 2, the Sai Parenterals share price was trading at ₹652.95, up 6.67%.

The sharp move came as investors reacted to the size and duration of the agreement, which provides long-term revenue visibility through a multi-year supply arrangement rather than a one-off export order.

For a pharmaceutical company of Sai Parenterals’ scale, a contract of this magnitude with an overseas customer significantly expands its international order pipeline and strengthens its presence in regulated export markets.

Agreement Marks a Major Export Milestone

The contract is centred on the exclusive supply of OTC medicines, a segment where consistent product quality, regulatory compliance and uninterrupted deliveries are critical for maintaining long-term customer relationships.

With operations spanning more than seven years and the possibility of an extension, the agreement provides Noumed Pharmaceuticals with a stable commercial platform in Australia. The deal also reflects the subsidiary’s ability to compete for large international supply mandates in regulated healthcare markets.

While the company has not shared a detailed execution schedule or annual revenue breakup, the contract is expected to be serviced over its tenure rather than recognised upfront.

Conclusion

The Australian supply agreement marks a significant milestone for Sai Parenterals’ international business. Beyond its headline value, the contract establishes a long-term relationship with a major overseas pharmacy network and could strengthen the company’s position in regulated export markets. Investors are likely to watch for updates on execution, product supplies and the financial contribution of the agreement in the quarters ahead.

Source:

• https://www.nseindia.com/get-quote/equity/SAIPARENT/Sai-Parenterals-Limited
• https://nsearchives.nseindia.com/corporate/SAIPARENTERALS_01072026164110_Disclosurebaggingoforders.pdf